MX2022007163A - Uso de inhibidores de atr en combinacion con inhibidores de parp. - Google Patents
Uso de inhibidores de atr en combinacion con inhibidores de parp.Info
- Publication number
- MX2022007163A MX2022007163A MX2022007163A MX2022007163A MX2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- inhibitors
- combination
- rnase
- atr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen métodos de tratamiento de un cáncer en un sujeto mediante el uso de un inhibidor de ATR e inhibidor de PARP, donde el cáncer se ha identificado anteriormente como un cáncer con una pérdida de función de ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, o una combinación de estos, o como un cáncer ALT+. También se describen métodos de inducción de la muerte celular en una célula cancerosa anómala con una pérdida de función de ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, o una combinación de estos, o una célula de cáncer ALT+, mediante la puesta en contacto de la célula con una cantidad eficaz de un inhibidor de ATR e inhibidor de PARP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946876P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/064662 WO2021119523A1 (en) | 2019-12-11 | 2020-12-11 | Use of atr inhibitors in combination with parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007163A true MX2022007163A (es) | 2022-08-25 |
Family
ID=76316464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007163A MX2022007163A (es) | 2019-12-11 | 2020-12-11 | Uso de inhibidores de atr en combinacion con inhibidores de parp. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210177856A1 (es) |
| EP (1) | EP4072551A4 (es) |
| JP (1) | JP2023506787A (es) |
| KR (1) | KR20220128350A (es) |
| CN (1) | CN115103677A (es) |
| AU (1) | AU2020402108A1 (es) |
| BR (1) | BR112022011426A2 (es) |
| CA (1) | CA3164203A1 (es) |
| CL (1) | CL2022001540A1 (es) |
| IL (1) | IL293810A (es) |
| MX (1) | MX2022007163A (es) |
| WO (1) | WO2021119523A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4355334A1 (en) * | 2021-06-16 | 2024-04-24 | Repare Therapeutics Inc. | Use of atr inhibitors in combination with parp inhibitors for treating cancer |
| WO2023193114A1 (en) * | 2022-04-07 | 2023-10-12 | Repare Therapeutics Inc. | Methods of using atr inhibitors |
| WO2023242302A1 (en) * | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
| CN117159725A (zh) * | 2023-04-06 | 2023-12-05 | 上海交通大学医学院附属仁济医院 | 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5545690B2 (ja) * | 2003-12-01 | 2014-07-09 | クドス ファーマシューティカルズ リミテッド | 癌治療のためのｄｎａ損傷修復阻害剤 |
| TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| WO2018153973A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors with parp inhibitors |
| CR20210281A (es) * | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| CR20220068A (es) * | 2019-07-22 | 2022-06-30 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr |
-
2020
- 2020-12-11 EP EP20898316.3A patent/EP4072551A4/en active Pending
- 2020-12-11 AU AU2020402108A patent/AU2020402108A1/en active Pending
- 2020-12-11 KR KR1020227023568A patent/KR20220128350A/ko unknown
- 2020-12-11 WO PCT/US2020/064662 patent/WO2021119523A1/en unknown
- 2020-12-11 MX MX2022007163A patent/MX2022007163A/es unknown
- 2020-12-11 CA CA3164203A patent/CA3164203A1/en active Pending
- 2020-12-11 CN CN202080096191.XA patent/CN115103677A/zh active Pending
- 2020-12-11 JP JP2022535631A patent/JP2023506787A/ja active Pending
- 2020-12-11 US US17/119,512 patent/US20210177856A1/en not_active Abandoned
- 2020-12-11 BR BR112022011426A patent/BR112022011426A2/pt unknown
- 2020-12-11 IL IL293810A patent/IL293810A/en unknown
-
2022
- 2022-06-09 CL CL2022001540A patent/CL2022001540A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220128350A (ko) | 2022-09-20 |
| EP4072551A1 (en) | 2022-10-19 |
| EP4072551A4 (en) | 2023-11-15 |
| WO2021119523A1 (en) | 2021-06-17 |
| CN115103677A (zh) | 2022-09-23 |
| CA3164203A1 (en) | 2021-06-17 |
| WO2021119523A8 (en) | 2021-08-05 |
| IL293810A (en) | 2022-08-01 |
| US20210177856A1 (en) | 2021-06-17 |
| BR112022011426A2 (pt) | 2022-08-30 |
| CL2022001540A1 (es) | 2023-01-13 |
| AU2020402108A1 (en) | 2022-07-14 |
| JP2023506787A (ja) | 2023-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007163A (es) | Uso de inhibidores de atr en combinacion con inhibidores de parp. | |
| BR112023024942A2 (pt) | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer | |
| CR20200527A (es) | Compuestos dirigidos a brm y metodos de uso asociados | |
| MX2019011431A (es) | Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1). | |
| NZ748192A (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| WO2017197153A8 (en) | Combination therapies of hdac inhibitors and pd-1 inhibitors | |
| PH12018500869A1 (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2019011469A (es) | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| MX2019008545A (es) | Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa. | |
| MX2021006347A (es) | Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2. | |
| CL2021002262A1 (es) | Composiciones y métodos para tratar laminopatías | |
| PH12020551995A1 (en) | Modulator of apol1 expression | |
| MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
| MX2020006892A (es) | Composiciones para crioconservación y métodos de uso de estas. | |
| NZ738876A (en) | Motile sperm domain containing protein 2 and inflammation | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2021013271A (es) | Inhibidores de la via rank en combinacion con inhibidores de cdk. | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| MX2021001870A (es) | Metodo para tratar cancer pancreatico. | |
| MX2020011002A (es) | Combinacion que comprende inhibidor de hdac, inhibidor de lag-3 y un inhibidor de pd-1 o inhibidor de pd-l1 para el tratamiento del cancer. |